GHK-Cu is one of the smallest peptides people study — just three amino acids (the building blocks of proteins) joined together and carrying a single atom of copper. Its full name is copper–glycyl-L-histidyl-L-lysine, usually shortened to GHK-Cu. Unlike most research peptides, it isn't foreign to the body: your own blood contains it, and levels fall as you age. It's studied mostly for skin and wound healing — but with an important catch about *how* it's been tested.
In plain terms: a natural, age-declining copper peptide with real skin-science behind it — most of it from creams and lab dishes, not injections.
What it is
GHK stands for its three amino acids: Glycine, Histidine, and Lysine. On its own that trio is just "GHK." The biologically active form pairs it with a copper ion (written Cu, hence "GHK-Cu") — copper is the part that switches on much of its activity2. So GHK-Cu is a copper-carrying tripeptide.
It was discovered in 1973 by Loren Pickart, who was trying to explain a striking observation: human liver cells kept alive in a dish survived longer when bathed in blood serum from young donors than from old donors. He tracked that "youth" effect down to a small peptide in the serum — GHK1.
It declines with age
GHK is found naturally in blood plasma, saliva, and urine. Its plasma level is roughly 200 ng/mL at age 20, falling to about 80 ng/mL by age 602. That decline lines up with the body's fading ability to repair itself — which is the core idea behind studying it: could restoring GHK restore some of that regenerative signalling?
How it's thought to work
In laboratory and animal studies, GHK-Cu shows up as a tissue-repair signal. The reported effects include:
- Collagen and skin matrix — it prompts fibroblasts (skin cells) to make more collagen and glycosaminoglycans, the molecules that give skin its structure and springiness2.
- Wound healing — it attracts repair and immune cells to an injury and supports the rebuilding of damaged tissue2.
- Angiogenesis — angiogenesis is the growth of new blood vessels; GHK-Cu has been reported to promote it, which would bring more blood supply to healing tissue3.
- Gene signalling — gene-expression studies found GHK can shift the activity of a large number of genes, including some tied to tissue repair and, in cell studies, tumour-suppression pathways3.
In plain terms: in the lab it behaves like a "repair, please" message to skin and connective tissue. Treat that as a strong lead from cells and animals — not a proven human treatment.
What the studies actually found
Two things stand out about GHK-Cu's evidence base. First, a lot of it is genuinely old and foundational. Second, much of the influential work comes from a single researcher's group — a point worth keeping in mind, the same way it is for other research peptides:
| Study | Model / level | What it showed | Year |
|---|---|---|---|
| Pickart & Thaler1 | Human serum + liver cells (dish) | Isolated the tripeptide; young-donor serum kept liver cells alive longer | 1973 |
| Pickart et al. — review2 | Review (cell + animal) | GHK stimulates collagen and glycosaminoglycans, wound healing, and repair-related gene activity | 2015 |
| Pickart & Margolina — review3 | Review (cell + animal + topical skin) | Skin-regenerative effects; explored anti-cancer gene signatures in cell studies | 2018 |
The pattern: consistent, encouraging signals for skin and tissue repair — largely from cell cultures, animals, and topical (on-the-skin) studies, much of it reviewed by the same group that discovered the peptide.
The honest catch: topical vs injected
This is the part vendor pages blur. Most of the human-relevant GHK-Cu evidence is cosmetic and topical — creams and serums applied to skin, where it has a real track record in dermatology research. The injectable, whole-body use that shows up in the peptide scene is a different proposition: there is very little controlled human data for systemic GHK-Cu, and its effects there rest mainly on the cell and animal work.
A related quirk: GHK is cleared from the bloodstream very quickly — it circulates only briefly before being broken down or bound up2. So a systemic dose does not linger the way a weekly GLP-1 medicine does.
In plain terms: strong story for skin creams; thin story for injections.
Regulatory status
GHK-Cu is not an approved medicine. In the US, injectable GHK-Cu was placed on the FDA's Category 2 bulk-substances list for compounding pharmacies — the same restrictive category applied to peptides like BPC-157 — meaning compounding it carried regulatory risk4. That status has been under active review, so it is genuinely a moving picture as of 2026 rather than a settled one. Topical cosmetic use sits under different rules from injectables. This page takes no position on sourcing and never discusses where to obtain anything.
Latest research
- The 2015 and 2018 Pickart reviews remain the most-cited syntheses, pulling together decades of cell, animal, and topical-skin work on collagen, wound healing, and gene signalling23.
- Independent, controlled human trials of injectable GHK-Cu are still largely missing — the biggest gap in the evidence, and the reason its systemic effects stay in the "promising but unproven" column.
- Its US compounding status is in flux as the FDA re-evaluates the peptide bulk-substances lists. We update this section as that resolves.
The short version
GHK-Cu is a natural copper tripeptide, discovered in 1973, that our own blood carries in declining amounts as we age. Cell, animal, and topical-skin studies tie it to collagen production, wound healing, and blood-vessel growth — but the human evidence is mostly cosmetic and topical, and injectable whole-body evidence is thin. It's a research compound, not a medicine, and its compounding status is under review. Educational overview only. For context, see what are research peptides.